OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial von Diener, HC, Dodick, DW, Aurora, SK, Turkel, CC, DeGryse, RE, Lipton, RB, Silberstein, SD, Brin, MF

Volltext

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial von Aurora, SK, Dodick, DW, Turkel, CC, DeGryse, RE, Silberstein, SD, Lipton, RB, Diener, HC, Brin, MF

Volltext

Probability of Pulse Coincidence in a Multiple Radar Environment von Demos, George T., Weprin, Mark S.

Volltext

ANTICIPATORY STRESS AND FLIGHT STRESS IN F-102 PILOTS von Demos,George T, Hale,Henry B, Williams,Edgar W

Volltext bestellen

Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis von Yunusa, Ismaeel, Rashid, Nazia, Demos, George N., Mahadik, Bhargavi S., Abler, Victor C., Rajagopalan, Krithika

Volltext

Increased risk of falls and fractures in patients with psychosis and Parkinson disease von Forns, Joan, Layton, J Bradley, Bartsch, Jennifer, Turner, Mary Ellen, Dempsey, Colleen, Anthony, Mary, Ritchey, Mary E, Demos, George

Volltext

Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States von Forns, Joan, Danysh, Heather E, McQuay, Lisa J, Turner, Mary Ellen, Dempsey, Colleen, Anthony, Mary S, Demos, George, Layton, J. Bradley

Volltext

Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 partici... von Brin, Mitchell F., MD, Boodhoo, Terry I., MS, Pogoda, Janice M., PhD, James, Lynn M., MPH, Demos, George, MD, Terashima, Yasunori, MD, PhD, Gu, Juanhong, MS, Eadie, Nina, MBA, Bowen, Beta L., MS

Volltext

OnabotulinumtoxinA in Lower Limb Spasticity: Safety Results from a Pooled Analysis von Earl, Nancy, MD, MA, James, Lynn M., MPH, Shi, Genming, MD, Demos, George, MD, Dimitrova, Rozalina, MD, MPH

Volltext

Pimavanserin and concomitant anti‐dementia medication use in patients with neurodegenerative and/or neurovascular disorders: Safety outcomes from pooled clinical data and the HARMO... von Foff, Erin P., McEvoy, Bradley, Skoog, Benjamin, Demos, George

Volltext

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, doubl... von Ballard, Clive, Banister, Carol, Khan, Zunera, Cummings, Jeffrey, Demos, George, Coate, Bruce, Youakim, James M, Owen, Randall, Stankovic, Srdjan, Tomkinson, Elaine B, McDermid, Joanne, Ocal, Delik, Testad, Ingelin, Qayyum, Mustabshira A, Kemos', Polychronis, Borejko, Olga, Megalogeni, Maria, Brookes, Ella V, Petrava, Anya, Da Silva, Miguel, Nunez, Kayleigh

Volltext

Motor function in patients with neuropsychiatric manifestations of neurodegenerative disease treated with pimavanserin (4531) von Weintraub, Daniel, Foff, Erin P., Ballard, Clive, McEvoy, Bradley, Coate, Bruce, Demos, George, Berrio, Ana, Abbs, Brandon, Youakim, James M., Stankovic, Srdjan

Volltext

Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease (NDD): results from 4 placebo-controlled clinical studies (2369) von Ballard, Clive, Foff, Erin P., Tariot, Pierre, McEvoy, Bradley, Coate, Bruce, Demos, George, Berrio, Ana, Abbs, Brandon, Youakim, James M., Stankovic, Srdjan

Volltext

Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed von Citrome, Leslie, Norton, James C., Chi-Burris, Kathy, Demos, George

Volltext

152 Pimavanserin for the Treatment of Parkinson’s Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed von Citrome, Leslie, Norton, James, Chi-Burris, Kathy, Demos, George

Volltext

Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis (2096) von Ballard, Clive, Kreitzman, David, Isaacson, Stuart, Norton, James, Demos, George, Liu, I-Yuan, Fernandez, Hubert, Ilic, Tihomir, Azulay, Jean, Ferreira, Joaquim, Abler, Victor, Stankovic, Srdjan

Volltext

Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis von Ballard, Clive G., Kreitzman, David L., Isaacson, Stuart, Liu, I-Yuan, Norton, James C., Demos, George, Fernandez, Hubert H., Ilic, Tihomir V., Azulay, Jean-Philippe, Ferreira, Joaquim J., Abler, Victor, Stankovic, Srdjan

Volltext

Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications von Naumann, Markus, Carruthers, Alastair, Carruthers, Jean, Aurora, Sheena K., Zafonte, Ross, Abu-Shakra, Susan, Boodhoo, Terry, Miller-Messana, Mary Ann, Demos, George, James, Lynn, Beddingfield, Frederick, VanDenburgh, Amanda, Chapman, Mary Ann, Brin, Mitchell F.

Volltext

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study von Layton, J. Bradley, Forns, Joan, Turner, Mary Ellen, Dempsey, Colleen, Bartsch, Jennifer L., Anthony, Mary S., Danysh, Heather E., Ritchey, Mary E., Demos, George

Volltext

OnabotulinumtoxinA in Lower Limb Spasticity: Safety Results from a Pooled Analysis (P03.266) von Earl, Nancy, James, Lynn, Li, Hung-Ir, Shi, Genming, Demos, George, Dimitrova, Rozalina

Volltext